Compare DLTH & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | TARA |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7M | 159.6M |
| IPO Year | 2015 | 2014 |
| Metric | DLTH | TARA |
|---|---|---|
| Price | $3.89 | $2.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $5.00 | ★ $25.33 |
| AVG Volume (30 Days) | 43.4K | ★ 760.0K |
| Earning Date | 12-15-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | 38.25 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $565,184,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $2.09 |
| 52 Week High | $5.09 | $7.82 |
| Indicator | DLTH | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 44.38 |
| Support Level | $3.75 | $2.19 |
| Resistance Level | $4.17 | $2.72 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 13.04 | 45.08 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.